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Abstract
Introduction: The fate and whereabouts of the allogenic mesenchymal stem cells (MSCs) following their
transplantation are not well understood. The present study investigated the fate of systemically administrated
allogeneic MSCs in mouse fracture healing by using in vivo imaging and immunohistochemistry methods.
Methods: Open femoral fracture with internal fixation was established in 30 FVB mice, which were assigned to
three groups receiving phosphate-buffered saline (PBS) injection, MSC systemic injection, or MSC local injection.
Luc-MSCs (5 × 105) isolated from the luciferase transgenic mice with FVB background were injected at 4 days after
fracture. All animals were terminated at 5 weeks after fracture; examinations included bioluminescence-based
in vivo imaging, micro-computer tomography, mechanical testing, histology, immunohistochemistry, and double
immunofluorescence staining.
Results: The bioluminescence signals of the Luc-MSCs at the fracture site could be detected for 12–14 days
following their injection in the Luc-MSC local injection group, whereas in the Luc-MSC systemic injection group,
Luc-MSCs were initially trapped in lungs for about 8–9 days and then gradually redistributed to the fracture site.
Bone mineral density, bone volume/tissue volume, ultimate load, and E-modulus in the MSC injection groups
were significantly higher than those in the PBS group. Double immunostaining demonstrated that the MSC local
injection group had more Luc-positive cells, and there was a higher apoptotic rate at the fracture site than the
MSC systemic injection group. Both Luciferase-positive MSCs and osteoblasts were present in the callus in the
MSC injection groups at 5 weeks after fracture, suggesting that some of allogenic Luc-MSCs contributed to the
new bone formation. Only less than 3 % of injected Luc-MSCs remained at the fracture site in the MSC injection
groups at 5 weeks following the fracture, and the rest of the injected Luc-MSCs disappeared.
Conclusions: Our data showed that both systemic and local injection of allogeneic MSCs promoted fracture
healing through enhancing biomechanical properties, bone content, and enlarged callus sizes.
Immunohistochemistry confirmed that the injected MSCs are still present in the fracture site and can differentiate
into osteoblasts to participate in fracture healing even at 5 weeks following the fracture. These findings provide
useful information for the use of allogenic MSCs for cell therapy applications.
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Introduction
Mesenchymal stem cells (MSCs), also known as multipo-
tent mesenchymal stromal cells, have the innate ability to
self-renew and differentiate into multiple cell types such
as neurons, osteoblasts, cardiomyocytes, adipocytes, and
chondrocytes when exposed to proper stimuli [1, 2], and
MSCs applied locally have been used for treatments of
various diseases [3–6]. Compelling evidence shows that
MSC local application could repair tissue defects [7–9]
and that MSCs are a promising cell source for tissue
engineering [10, 11].
Although the use of autologous MSCs for cell therapy
has been well established and accepted, the need of pro-
longed time for MSC culture to obtain therapeutic dose
and the narrow time window for their optimal applica-
tions prohibit their wider applications. Thus, allogenic
MSCs become an ideal alternative as they can be well
prepared in advance, banked, and made readily available
for use. However, the function and fate of allogeneic
MSCs in vivo are still not well defined. Intravenous de-
livery of allogenic MSCs results in their specific migra-
tion to sites of injury and improves recovery in animal
models of skin injury [12], stroke, and myocardial infarc-
tion [13–16]. In 2005, Shirley et al. reported that there
was a systemic mobilization and recruitment of osteo-
blastic precursors to the fracture site via the peripheral
circulation [17]. Caplan et al. also reported that MSCs
delivered systemically via the circulatory system can
home to target sites [18]. Taken together, allogenic
MSCs applied locally and systemically could promote
tissue (fracture) healing regeneration.
However, the function and fate of allogeneic MSCs
in vivo are still not well defined. Some reports supported
that MSCs mediate tissue and organ repair by replacing
damaged cells [19, 20], and other studies suggest that allo-
geneic MSCs mainly play immune-modulatory roles
in vivo [21–23]. Le Blanc et al. showed that MSCs could
suppress the proliferation of both CD4+ and CD8+ T cells
by upregulating the release of soluble factors such as
interleukin-10 and prostaglandin E2 [24]. It was also re-
ported that allogeneic MSCs encouraged repair through
the production of trophic factors, cytokines, and antioxi-
dants [25–27]. Kellie et al. also found that MSC treatment
increased the tensile strength of wounds and increased
production and deposition of collagens in the wound [28].
There are still issues of allogenic MSC application that
need further investigation: What is the fate of the allo-
genic MSCs in vivo? How long they can function and
survive in vivo? Is there any potential immunogenic ef-
fects caused by the allogenic MSCs? In the present
study, we investigated the fate and effects of systemically
administrated allogeneic MSCs versus local administra-




The chemicals used were all purchased from Sigma-
Aldrich (St. Louis, MO, USA) except where specified.
Animal details
Bone marrow-derived Luc-MSCs were isolated from 4-
week-old female CMV-luc mice (FVB/N background;
Xenogen Corporation, now part of Caliper Life Sciences,
Hopkinton, MA, USA). Thirty FVB/N male mice
(8 weeks old, body weight of 25–35 g) were used for
fracture study. All mice were housed in a designated,
government-approved animal facility at the Chinese
University of Hong Kong in accordance with the Chinese
University of Hong Kong animal experimental regulations,
and all animal experiments were approved by the Animal
Research Ethics Committee of the authors’ institution.
Isolation and cultivation of mouse bone marrow-derived
Luc-MSCs
The CMV-luc mouse was humanely terminated. Both
tibias and femurs were excised, muscle and connective
tissues were removed, and then bones were stored on ice
in phosphate-buffered saline (PBS) with 1 % penicillin-
streptomycin-neomycin (PSN). Under the laminar flow in
a biological safety cabinet, two ends of bone were excised,
and the marrow cavity was repeatedly flushed by 5 ml of
alpha complete culture medium (with 15 % fetal bovine
serum, 1 % PSN). All of the bone pieces were removed
from the 100-mm culture dish by forceps and then incu-
bated at 37 °C in a 5 % CO2 incubator for 5 days. The
initial spindle-shaped cells appeared on day 3 under
phase-contrast microscopy and then reached 70–90 %
confluence within 2 days. Cells were trypsinized and re-
plated by splitting at a ratio of 1:3 into new dishes. MSCs
between passages 4–8 were used in this study. MSC
markers CD44 and CD90, endothelial cell marker CD31,
and hematopoietic marker CD45 were examined by flow
cytometry in accordance with a previously published art-
icle [26]. The osteogenic and adipogenic differentiation
abilities were characterized by Alizarin red and Oil red O
staining after the corresponding inductions in accordance
with our previously published article [29].
Animal surgery
A mouse open transverse femoral fracture model with
internal fixation was used. In brief, the mice were under
general anesthesia and sterile conditions, and a lateral
incision through shaved skin and fascia lata from the left
knee to the greater trochanter was made. The plane
between the vasti and hamstrings was then opened by
blunt dissection to expose the femur. The exact
centralization of the transverse osteotomy was made by
hand saw. A small incision was opened at the knee
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level, and a hole was drilled at the inter-condylar notch
by using a 23-gauge hypodermic needle. A custom-
made stainless pin (diameter of 0.7 mm) was inserted
into the right femoral bone marrow cavity at the knee
level to fix the fracture. The incision was closed, and a
radiography was then taken to confirm the fracture.
After the surgery, the 30 mice were randomly assigned
into one of three groups: the Luc-MSC local injection
group (Loc group), the Luc-MSC systemic injection
group (Sys group), or the PBS control group (PBS
group); 10 mice were in each group.
Cell injection
In this study, we used cardiac injection of MSCs directed
by an ultrasound imaging system (Vevo 770; VisualSonics
Inc., Toronto, ON, Canada) instead of intravenous injec-
tion, based on the following reasons: (1) the blood vessels
in the mouse tail vein are thin; therefore, it is hard to be
penetrated by the needle; moreover, the needle may break
the vessel, resulting in cell leaking. (2) Our preliminary
study showed that the cells injected through either the tail
vein or the heart all ravel to the lungs within minutes of
injection. There are more cells trapped in the lungs in the
vein injection group comparing to the heart injection
group.
Cells and PBS injection were carried out at 4 days
after fracture. For the Luc-MSC systemic injection
group, 5 × 105 Luc-MSCs (in 100 μl of PBS) were
injected into the left ventricle through heart puncture
under the ultrasound imaging system; mice in the PBS
control group were given 100 μl of PBS injection
through heart puncture as above; for the local injection
group, 5 × 105 Luc-MSCs (in 100 μl of PBS) were dir-
ectly injected into the fracture site.
In vivo bioluminescent assays
After cell injection, five mice per Loc and Sys group
were intra-peritoneally injected with D-Luciferin
(15 mg/ml, 300 μl for a 30-g mouse). After 10 minutes,
mice were subjected to the IVIS imaging examination,
and the region of interest (ROI) was set in each image.
The same parameter settings for IVIS imaging were used
for all samples in this study: f number: 1, field of view:
22, binning factor: 16, luminescent exposure (seconds):
10. Mice were examined by IVIS imaging system every
2 days and thereafter until the signal disappeared. The
rate of photons per second of ROI was calculated by
IVIS software, the data were then analyzed by SPSS stat-
istical software, and the intensity of the signal was
expressed as percentages of photons per second of ROI.
To minimize the variations between individuals for IVIS
imaging detection, the IVIS 200 system was calibrated
each day for the first use in accordance with the manu-
facturer’s manual, and all the IVIS in vivo imaging
detection was carried out by two investigators who were
blinded to the groups of animals tested (with animal
coding unknown to the IVIS imaging machine operator).
Micro-computer tomography examination
All 30 mice were terminated at 5 weeks after fracture.
Eight mice per group were randomly chosen for micro-
CT analysis. Right femurs of all 30 mice were excised;
muscles, soft tissues, and the internal stainless pins
were carefully removed. For image acquisition, 300
two-dimensional (2D) micro-tomographic slices with a
20-μm slice increment covering a total range of 6 mm
were scanned by Scanco Medical μCT40 (Scanco Ltd.,
Brüttisellen, Switzerland). Two hundred fifty sequential
slices of 2D CT images at 2.5 mm proximal and
2.5 mm distal to the fracture line were selected, and the
contoured region including the cortical diaphyseal bone
and endosteal callus was set in each image. A low-pass
Gaussian filter (Gauss sigma = 0.8 and Gauss support = 1)
was used to partly suppress the noise in the volumes. The
high- and low-radio-opacity mineralized tissues were seg-
mented by thresholding, and an appropriate threshold was
determined from the grayscale CT images. Bone volume
(BV), tissue volume (TV), BV/TV, and mean volumetric
bone mineral density for each sample were recorded.
Three-point bending mechanical testing
Tests were performed within 24 hours after excision at
room temperature, and fractured femurs were tested to
failure with a constant displacement rate of 4 mm/minute
by a three-point bending device (H25KS; Hounsfield Test
Equipment Ltd., Redhill, Surrey, UK). The femurs were
loaded in the anterior-posterior direction with the span of
the two support points set as 8 mm. The force loading
point was set at the fracture site. After testing, the load-
displacement curves of the femurs were generated by the
built-in software (QMAT Professional Material testing
software; Hounsfield Test Equipment Ltd.); ultimate load
to failure, energy absorbed to failure (the area under the
load-displacement curves, known as the toughness), and
the modulus of elasticity (E-Modulus, the slope of the
stress-strain curve, known as the tissue stiffness) [30] were
recorded and analyzed by the software.
Histology and immunohistochemistry
The fractured femurs were fixed in 4 % buffered formalin
for 1 day and then decalcified with 9 % formic acid for 5-7
days. Attempts were made to standardize the sectioning at
a mid-sagittal plane of each specimen by cutting the speci-
men in half (longitudinally in a sagittal plane) by using a
slicing blade. Samples were subjected for tissue processing
and then embedded in paraffin. Thin sections (5 μm) were
cut on a Rotary Microtome (HM 355S; Thermo Fisher
Scientific, Dreieich, Germany) along the long axis of each
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Fig. 1 In vivo tracking systemically injected Luc-MSCs. a, b During the first hour following the injection, Luc-MSCs spread throughout the whole
body via circulating system, and high concentrations of Luc-MSCs were observed in limbs, lungs, and oral cavity. c, d After about 1 hour following
the injection, high concentrations of Luc-MSCs were observed only at the lung site, but no signal was observed at limbs, the oral cavity, and other
parts of the body. e At day 4 following the injection, one mouse was terminated, and strong signals were observed at excised lungs, but no signal was
observed on the excised fractured femur and other organs. f At day 11 following the injection, another mouse was terminated; no signal was observed
throughout the whole body, including the lung site. Luc-MSC Luciferase labeled mesenchymal stem cell
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femur in the sagittal plane. Sections were mounted on
the coated slides. Paraffin was removed by immersing
the slides in Xylene 2 changes of 5 minutes at room
temperature. Slides were then taken through graded
ethanol and distilled water. For antigen retrieval, slides
were immersed in 10 mM of citrate buffer at 60 °C for
20 minutes and then rinsed with PBS twice; the slides
were then immersed in 3.0 % hydrogen peroxide in PBS
for 5 minutes and rinsed twice with PBS for 5 minutes
each.
TUNEL assay and immunofluorescence staining
A peroxidase in situ apoptosis detection kit (catalog
number S7100; EMD Millipore, Billerica, MA, USA)
was used to detect the apoptosis level of injected Luc-
MSCs. In brief, following the step above, slides were
taken through equilibration buffer for 10 seconds and
TDT enzyme in a humidified chamber at 37 °C for
1 hour. The slides were washed in PBS buffer for 10 -
minutes, then anti-digoxignenin conjugate was applied
on the slides for 30 minutes, and this was followed by
PBS washing and peroxidase substrate incubation for
6 minutes. The slides were finally counterstained in
0.5 % (wt/vol) methyl green for 10 minutes and washed
in PBS. For detection of Luc-MSCs on the same slide,
we performed immunostaining. Briefly, the counter-
stained slides were blocked by 5 % donkey serum in
1 % bovine serum albumin (BSA) for 20 minutes and
then incubated with the goat anti-Luciferase antibody
(1:300; Santa Cruz Biotechnology, Inc., Dallas, TX,
USA) overnight at 4 °C. Slides were washed with PBS
three times, incubated with the donkey anti-goat IgG-
FITC (1:1000; Santa Cruz Biotechnology, Inc.) for
60 minutes at room temperature in the dark, and
washed and mounted. The fluorescent cells were visual-
ized by using a fluorescent microscope (Zeiss-spot; Carl
Zeiss MicroImaging GmbH, Jena, Thuringia, Germany).
Double immunofluorescence staining
We used two antibodies in one slide. In brief, slides were
blocked by 5 % donkey serum in 1 % BSA for 20 minutes,
incubated with the goat anti-Luciferase antibody (1:300;
Santa Cruz Biotechnology, Inc.) and the rabbit anti-
Osteocalcin antibody (1:300; Santa Cruz Biotechnology,
Inc.) or the rabbit anti-Nestin antibody (1:300; Sigma-
Aldrich) overnight at 4 °C, washed with PBS three times,
and incubated with the donkey anti-goat IgG-FITC
(1:1000; Santa Cruz Biotechnology, Inc.) and Cy3 donkey
anti-rabbit IgG (1:1000; Life Technologies, Carlsbad, CA,
USA) for 60 minutes at room temperature in the dark.
Fig. 2 In vivo tracking Luc-MSCs in the systemic injection group. a–d The intensity of the signal at the lung site decreased gradually with time,
and the signal lasted about 8–9 days following the systemic injection. e Quantitative analysis of the photons at the lung site also confirmed the
above-mentioned phenomena. f At day 5–8 following the injection, very weak signals were observed at the fracture site and lasted 1–3 days.
Luc-MSC Luciferase labeled mesenchymal stem cell
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Slides were washed with PBS three times, counterstained
with 4′,6-diamidino-2-phenylindole (DAPI), mounted,
and examined under fluorescent microscope.
Quantitation of injected Luc-positive cells at the fracture
site
The image with the maximum callus width in each
sample was chosen for cell counting. Briefly, the image
was opened by ImageJ version 1.48 (National Institute
of Mental Health, Bethesda, MD, USA); when “Plugins/
Analyze/Cell Counter” plugin is run, the Crosshair
(mark and count) tool was used to manually count
apoptotic and immunofluorescence-labeled cells. The
cell counting result was generated by the software.
Statistical analysis
All quantitative data were transferred to statistical spread-
sheets and analyzed by a commercially available statistical
program: SPSS version 16.0 (IBM Corporation, Armonk,
NY, USA). One-way analysis of variance followed by post
hoc test was used for comparison of mean values, and
P values of less than 0.05 were considered statistically
significant.
Results
The characterization of MSCs
The flow cytometry results confirmed that isolated Luc-
MSCs were negative for hematopoietic marker CD45
(Additional file 1: Figure S1A) and endothelial cell
marker CD31 (Additional file 1: Figure S1B) and homo-
genously positive for MSC markers CD44 and CD90
(Additional file 1: Figure S1C, D). In differentiation
assays of Luc-MSCs, the Alizarin red staining demon-
strated that mineralized nodules formed after 3 weeks of
the osteogenic induction (Additional file 1: Figure S1E);
intracellular Oil red O-stained lipid-rich vacuoles appeared
after 2 weeks of the adipogenic induction (Additional file 1:
Figure S1F).
In vivo bioluminescent assays
In the systemic injection group at the first hour following
injection, Luc-MSCs spread throughout the body via cir-
culating system, and higher concentrations of Luc-MSCs
were seen in limbs, lungs, and oral cavity (Fig. 1a, b). After
1 hour following the injection, the Luc-MSCs aggregated
in the lungs, and the signal at limbs, oral cavity, and other
locations of the body was diminished (Fig. 1c, d). At day 4
following the injection, one mouse was terminated; the
lungs, femurs, heart, liver, and kidney were excised and
Fig. 3 In vivo tracking Luc-MSCs in the local injection group. a–e The intensity of the signal at the fracture site decreased gradually with time,
and the signal lasted about 12–14 days following the injection. f Quantitative analysis of the photons at the fracture site also confirmed the
above-mentioned phenomena. Luc-MSC Luciferase labeled mesenchymal stem cell
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scanned by using the IVIS system; a strong signal was seen
in the lungs, but none was seen at the fractured femur
and other organs (Fig. 1e). At day 11 following the injec-
tion, another mouse was terminated, and there was no sig-
nal throughout the whole body, including the lung site
(Fig. 1f). Figure 2a–d showed that the intensity of the sig-
nal at the lung site decreased gradually with time, and the
detectable signals lasted about 8–9 days following the in-
jection. Quantitative comparison of photons at different
time points confirmed the continuous disappearance of
the Luc-MSCs in the lungs (Fig. 2e). At day 5–8 following
the injection, weak signals appeared at the fracture site
(Fig. 2f) and lasted 1–3 days and then disappeared.
In the local injection group, the intensity of the signal at
the fracture site decreased gradually with time, and the
signal lasted about 12–14 days following the injection
(Fig. 3a, b, c, d, e) and that was confirmed by quantitative
comparison of photons at different time points (Fig. 3f).
Micro-CT analysis of the fractured bone
Quantitative analysis revealed that the mean density of
bone volume in the PBS control group was significantly
lower than that of the MSC systemic injection group
(P < 0.05) and the MSC local injection group (P < 0.05),
but there was no significant difference between the
MSC systemic injection group and the MSC local injec-
tion group (Fig. 4a). The bone volume over tissue vol-
ume (BV/TV) in the MSC local injection group was
significantly higher than that of the PBS control group
(P < 0.05), but there was no significant difference be-
tween the MSC systemic injection group and the MSC
local injection group (Fig. 4b).
Three-point bending mechanical testing
E-Modulus (known as the tissue stiffness) in the MSC
local injection group was significantly higher than that of
the PBS control group (P < 0.05), but there was no signifi-
cant difference between the MSC systemic injection group
and the MSC local injection group (P > 0.05) and also no
significant difference between the PBS control and the
MSC systemic injection group (P > 0.05) (Fig. 4c).
Ultimate load to failure in the MSC systemic injection
group was significantly higher than that of the PBS con-
trol group (P < 0.05), and the MSC local injection group
was significantly higher than that of the PBS control
group (P < 0.05), but there was no significant difference
between the MSC systemic injection group and the
MSC local injection group (P > 0.05) (Fig. 4d). Energy
absorbed to failure (known as the toughness) did not
Fig. 4 Micro-CT and three-point bending mechanical testing. a BV in the PBS control group was significantly lower than that of the MSC systemic
injection group (P < 0.05) and the MSC local injection group (P < 0.05). b BV/TV in the MSC local injection group was significantly higher than that
of the PBS control group (P < 0.05). c E-Modulus in the MSC local injection group was significantly higher than that of the PBS control group (P < 0.05).
d Ultimate load to failure in the MSC systemic injection group was significantly higher than that of the PBS control group (P < 0.05), and the MSC local
injection group was significantly higher than that of the PBS control group (P < 0.05). e Energy absorbed to failure did not show any significant
difference among these three groups (P > 0.05). BV bone volume, Luc-MSC Luciferase labeled mesenchymal stem cell, Micro-CT micro-computed
tomography, MSC mesenchymal stem cell, PBS phosphate-buffered saline, TV tissue volume
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show any significant difference among these three groups
(P > 0.05) (Fig. 4e).
Detection of apoptotic Luc-MSCs
To examine the apoptosis level of injected Luc-MSCs, per-
oxidase staining and immunofluorescence staining were
carried out on the same section. A mass of apoptotic cells
(brown cells) was observed around the fracture sites
within the callus in the Luc-MSC systemic injection group
(Fig. 5a), the local injection group (Fig. 5b), and the PBS
control group (Fig. 5c) at 5 weeks following the fracture,
but none was observed in the negative control (the normal
femur) (Fig. 5d).
High-resolution images were respectively enlarged from
the red outlined areas in Fig. 5a, b, c, d (Fig. 5e, f, g, h).
Both living Luc-positive cells (light green cells within red
circles) and apoptotic Luc-positive cells (dark green cells
within white circles) were found in the MSC systemic
injection group (Fig. 5e) and the MSC local injection
group (Fig. 5f) at 5 weeks following the fracture, but no
Fig. 5 Illustration of apoptotic cells at the fracture site. A mass of apoptotic cells (brown cells) was observed around the fracture ends within the
callus in the Luc-MSC systemic injection group (a), the local injection group (b), and the PBS control group (c) at 5 weeks following the fracture,
but none was observed in the negative control (the normal femur) (d). e-h High-resolution images were, respectively, enlarged from the red
outlined areas in a–d. Both living Luc-positive cells (light green cells within red circles) and apoptotic Luc-positive cells (dark green cells within
white circles) were found in the MSC systemic injection group (e) and the MSC local injection group (f) at 5 weeks following the fracture, but no
Luc-positive cells were found in the PBS control group (g) and the negative control (h). Luc-MSC Luciferase labeled mesenchymal stem cell, MSC
mesenchymal stem cell, PBS phosphate-buffered saline
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Luc-positive cells were found in the PBS control group
(Fig. 5g) and the negative control (Fig. 5h).
Double immunofluorescence staining for Luc/Nestin and
Luc/Osteocalcin
To examine the co-distribution of luciferase (FITC immu-
nolabeling) and Nestin (Cy3 immunolabeling), an MSC
marker, double immunofluorescence staining was carried
out on the same section. Luc+/Nestin+ cells, the red-
yellow cells pointed out by red arrows in Fig. 6a, were
observed in the MSC systemic injection group, which
meant that some systemic injected allogenic Luc-MSCs
had migrated to the fracture site via circulation system
and still maintain their phenotype at 5 weeks following
Fig. 6 Double immunofluorescence staining for Luc/Nestin and Luc/Osteocalcin (DAPI for nucleuses). a In the Sys group, Luc+/Nestin+ cells (the
red-yellow cells pointed out by red arrows), the systemically injected allogenic Luc-MSCs, had migrated to the fracture site. b In the Loc group,
Luc+/Nestin+ cells (red arrows), the injected Luc-MSCs through local sites, remained at 5 weeks following the fracture. Luc+/Nestin− cells (the
green cells pointed out by white arrows in a, b) were observed, which meant that some injected Luc-MSCs had differentiated to other types of
cells in both MSC injection groups. c, d Luciferase-positive cells were not observed in the PBS group (c) and the negative control (d), but Luc
−/Nestin+ cells (white arrows in c), autogenetic MSCs, existed in the callus in the PBS control group. e, f Luc+/Osteocalcin+ cells (the red-yellow
cells pointed out by red arrows) were observed both in the Sys group (e) and the Loc group (f), which meant that some injected Luc-MSCs had
differentiated to osteoblasts. Luc+/Osteocalcin− cells, the green cells (white arrows), were also found in MSC injection groups, which meant that
some injected Luc cells remained at 5 weeks following the fracture. g, h Luciferase-positive cells were not observed in the PBS control group (g)
and the negative control (h), but Luc−/Osteocalcin+ cells, autogenetic osteoblasts, were found in the callus. Scale bar: 20 μm. DAPI 4′,6-diamidino-
2-phenylindole, Luc-MSC Luciferase labeled mesenchymal stem cell, MSC mesenchymal stem cell, PBS phosphate-buffered saline
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the fracture. Luc+/Nestin+ cells (red arrows, Fig. 6b)
were observed in the MSC local injection group, which
meant that some injected Luc-MSCs through local sites
remained at 5 weeks following the fracture. Luc+/Nestin−
cells, the green cells pointed out by white arrows in Fig. 6a,
b, were also observed, which meant that some injected
Luc-MSCs had differentiated into other types of cells in
both MSC injection groups. Luciferase-positive cells were
not observed in the PBS control group (Fig. 6c) and the
negative control (without the primary antibodies) (Fig. 6d),
but Luc−/Nestin+ cells were found in the PBS control
group (white arrows in Fig. 6c), which meant that autoge-
netic MSCs existed at the fracture site in the PBS control
group.
Double immunofluorescence staining was also carried
out to examine the co-distribution of luciferase (FITC
immunolabeling) and Osteocalcin (Cy3 immunolabel-
ing), secreted solely by osteoblasts on the same section.
Luc+/Osteocalcin+ cells, the red-yellow cells pointed out
by red arrows, were observed in both the MSC systemic
injection group (Fig. 6e) and the MSC local injection
group (Fig. 6f ) at 5 weeks following the fracture, which
meant that some injected Luc-MSCs had differentiated
into osteoblasts at 5 weeks following the fracture and
contributed to the bone formation. Luc+/Osteocalcin−
cells, the green cells pointed out by white arrows in
Fig. 6e, f, were also found in both systemic and local
injection groups, which confirmed that some injected
Luc-positive cells remained at the fracture sites at 5 weeks
following the fracture. Luc-positive cells were not ob-
served in the PBS control group (Fig. 6g) and the negative
control (without primary antibodies) (Fig. 6h), but Luc
−/Osteocalcin+ cells were found in the PBS control group
(white arrows in Fig. 6g), which meant that autogenetic
osteoblasts existed at the fracture site at 5 weeks following
the fracture and contributed to the bone formation.
The number of injected Luc-positive cells at the fracture
site
Quantitative analysis revealed that the number of Luc-
positive cells in the callus in the MSC systemic injection
group was significantly lower than that of the MSC local
injection group (P < 0.05) (Fig. 7a). The proportion of
apoptotic Luc-positive cells in Luc-positive cells in the
Fig. 7 Comparison of the number of the injected Luc-positive cells at the fracture site at 5 weeks following fracture. a The number of Luc-positive cells
in the callus in the MSC systemic injection group was significantly lower than that of the MSC local injection group (P < 0.05). b The proportion of
apoptotic Luc-positive cells in Luc-positive cells in the MSC systemic injection group was significantly lower than that in the MSC local injection group
(P < 0.05). c The proportion of Luc-MSCs in Luc-positive cells in the MSC systemic injection group was significantly higher than that of the MSC local
injection group (P < 0.01). d The proportion of Luc-osteoblasts in Luc-positive cells did not show significant difference between the MSC systemic
injection group and the MSC local injection group (P > 0.05). Luc-MSC Luciferase labeled mesenchymal stem cell, MSC mesenchymal stem cell
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MSC systemic injection group was significantly lower
than that in the MSC local injection group (P < 0.05)
(Fig. 7b). The proportion of Luc-MSCs in Luc-positive
cells in the MSC systemic injection group was signifi-
cantly higher than that of the MSC local injection group
(P < 0.01) (Fig. 7c). The proportion of Luc-osteoblasts in
Luc-positive cells did not show a significant difference
between the MSC systemic injection group and the
MSC local injection group (P > 0.05) (Fig. 7d).
The minimal Luc cells that IVIS in vivo imaging system
could detect in vivo in mice
IVIS in vivo imaging systems, based on the principle of
bioluminescence, are widely used for in vivo tracking
and monitoring of Luciferase-expressing cells in recipi-
ent animals [29, 31]. However, it was reported that Lu-
ciferase expression was observed to decrease with time,
most likely the result of tissue rejection [32]. The light
signal detected on the surface of the mouse also depends
on the depth of the injected cells below the tissue sur-
face and the number of Luc cells. To test the sensitivity
and the accuracy of the IVIS imaging system, we sub-
cutaneously injected 1.5 × 104, 3 × 104, and 4.5 × 104
Luc-MSCs with luciferin, respectively, into three differ-
ent areas of the nude mouse and the FVB mouse (with
hair) (area I: 4.5 × 104 cells, II: 3 × 104 cells, III: 1.5 × 104
cells; Fig. 8), and then we monitored both mice by using
IVIS. The results showed that area III in the FVB mouse
did not show any signal under IVIS but did in the nude
mouse (Fig. 8). Concerning the foregoing results, in the
systemic injection group, the signal at the fracture site
was found only at day 5–8 following the injection by
IVIS; in the local injection group, the signal at the frac-
ture site lasted only 12–14 days; however, Luc-positive
cells could be found by immunofluorescence staining at
5 weeks following the fracture in both MSC injection
groups; therefore, in the present studies, we concluded
that the IVIS 200 in vivo imaging system was sensitive
to detect the number of the Luc cells above 1.5 × 104
in vivo in mice.
Discussion
Systemic and local injection of allogenic MSCs promoted
fracture healing equally in this study
Systemic injection is more appropriate for treatments of
systemic diseases such as osteoporosis, injuries involving
deeper sites, and poly-trauma; and local injection is sim-
pler for single and superficial injures such as skin wound
or burns [33]. The present study has demonstrated that
both systemic and local administration of allogeneic
MSCs promoted fracture repair significantly, and obvious
immune responses in this study were not observed in ei-
ther allogeneic MSC systemic or local administration.
Therefore, the use of allogeneic MSCs either systemically
or locally is effective in the mouse fracture model.
The explanations for the equal effects in promoting
fracture healing in both systemic and local injection
groups are that (1) the limited sample size used in this
Fig. 8 In vivo tracking injected Luc-positive cells by IVIS 200. Luc-MSCs (1.5 × 104, 3 × 104, and 4.5 × 104) with luciferin were subcutaneously injected
into three different areas of the nude and FVB (with hairs) mouse (area I: 4.5 × 104 cells, II: 3 × 104 cells, III: 1.5 × 104 cells). Luc cells (1.5 × 104) in the FVB
mouse cannot be found by IVIS 200. Luc-MSC Luciferase labeled mesenchymal stem cell, MSC mesenchymal stem cell
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study may not verify the small difference, (2) systemic-
ally and locally injected cells may contribute to the frac-
ture healing in different ways, (3) high dose of injected
cells ensured the equal effects, and (4) our data showed
that the number of systemically injected Luc cells at the
fracture site were significantly less than those of locally
injected Luc cells because of the blood barriers in the
lungs; however, the proportion of apoptotic Luc-positive
cells in Luc-positive cells in the MSC systemic injection
group was also significantly lower than that in the MSC
local injection group, which may be credited to the low
pH, hypoxia, inflammation, and infection in the local
environment.
The in vivo imaging is a very useful technique and an
invaluable tool to examine the living cells in vivo, and at
present the IVIS system is the best research tool for tra-
cing luciferase-labeled cells in vivo in small animals
(mice). However, there is a limitation of IVIS system,
and in the present study we found that the IVIS 200 sys-
tem was not sensitive enough to detect the number of
the Luc cells below 1.5 × 104 in vivo in mice; hence, the
use of immunohistochemistry methods to detect the
Luc-positive cells will be necessary to confirm the
whereabouts of the Luc-positive cells when the cells
numbers are expected to be lower.
The fate of engrafted MSCs
In vivo imaging data showed the following: (1) For heart
injection, MSCs spread throughout the whole body via
the circulating system in the early hours after the injec-
tion and aggregated into lungs, gradually decreased with
time, and disappeared after about 8–9 days. Injected
MSCs could be found at the fracture site at day 5–8 fol-
lowing the injection. (2) For local injection, engrafted
MSCs at the fracture site decreased gradually with time,
and the Luc cells disappeared at about 12–14 days fol-
lowing the injection.
Our double Immunofluorescence staining results
showed that both systemically and locally injected Luc-
MSCs were observed in the callus even at 5 weeks fol-
lowing the fracture, and some of them had differenti-
ated into osteoblasts and directly contribute to the
bone formation. However, as we discussed above, IVIS
200 was not sensitive to the number of the Luc cells
below 1.5 × 104 in vivo in the FVB mouse, which meant
that less than 3 % of injected Luc cells (1.5 × 104/5 × 105)
remained at the fracture site in the MSC injection groups
at 5 weeks following the fracture, and about half of these
cells went apoptosis in the callus. Our preliminary studies
also showed that the systemically injected Luc-MSCs were
not found in the heart, liver, kidney, and lungs by using
immunofluorescence staining at 5 weeks following the
fracture, which meant that almost 98.5 % of the
injected Luc cells were dead after 1 month following
the transplantation.
Conclusions
In this study, we tracked and estimated the systemically
and locally injected MSCs in both lungs and fracture
sites by using in vivo imaging system, which may give
guidance for the clinical transplantation of MSCs. Our
data also showed that both systemic and local adminis-
tration of allogeneic bone marrow-derived MSCs pro-
moted mouse fracture healing and enhanced callus
formation and their mechanical properties. However, we
have not understood the exact cellular and molecular
mechanisms behind the systemic allogeneic MSC admin-
istration in promoting fracture repair, and they still need
further investigations.
Additional file
Additional file 1: Figure S1. Cell surface markers and differentiation
capacities of mouse MSCs. (A) Flow cytometry analysis results confirmed
that isolated BM-MSCs were negative for hematopoietic marker CD45. (B)
Cells were negative for endothelial cell marker CD31. (C, D) Cells were
positive for MSC markers CD44 and CD90. (E) The Alizarin red staining
demonstrated that mineralized nodules formed after 4 weeks of the
osteogenic induction. (F) Intracellular Oil red O-stained lipid-rich vacuoles
appeared after 2 weeks of the adipogenic induction. BM-MSC bone
marrow-derived mesenchymal stem cell, MSC mesenchymal stem cell.
(TIFF 468 kb)
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